Treatments for are allergic fungal rhinosinusitis, bipolar I disorder, Hunter syndrome, Leber hereditary optic neuropathy, ovarian cancer, and schizophrenia under review.
In April 2025, CMG Pharmaceutical, a subsidiary of CHA Biotech, secured FDA approval for Mezofy (formerly Depipzo), an oral ...
Adjunctive agents for negative symptoms of schizophrenia are favored vs placebo, but their perceived efficacy decreases as study sample size increases. Effect size deflation in clinical trials ...
Risperidone was more effective at 2 weeks than quetiapine, aripiprazole, or ziprasidone in patients with schizophrenia. A comparison of the efficacy, tolerability, and discontinuation of antipsychotic ...
NEW YORK, Oct. 06, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced that three posters featuring new and previously reported ...
Department of Psychiatry, Psychotherapy, Psychosomatics and Psychological Medicine, University Clinic of Psychiatry I, Medical University Innsbruck, Innsbruck, Austria Neuroinflammation has been ...
The PANSS is currently the most established scale in patients with schizophrenia. For example in the high impact journal "Schizophrenia Bulletin" Kay's publication on the Positive and Negative ...
Seventy years of RCTs have failed to provide evidence that antipsychotics provide a clinically meaningful benefit for treating acute psychotic episodes. The authors of the JAMA Psychiatry article ...
PANSS SOLUTIONS PRIVATE LIMITED is a Private Limited Company, governed by the Companies Act as a company limited by shares. Classified as a Non-government company, it is registered under the Registrar ...
LOS ANGELES — The novel phosphodiesterase 10A (PDE10A) inhibitor known as CPL'36 (Celon Pharma) is effective and generally safe in acute exacerbations of schizophrenia, new research suggested. In a ...
Bristol Myers' schizophrenia drug Cobenfy stumbles as adjunctive treatment, denting blockbuster plan
Schizophrenia drug Cobenfy, a key component in Bristol Myers Squibb’s plan to navigate a transition period of major loss of exclusivity, has hit a phase 3 setback. Cobenfy as an adjunctive treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results